Sunshine Lake Pharma Reports P-I Study Results of Liraglutide Biosimilar RD12014 for Type 2 Diabetes
Shots:
- The company reported the P-I trial results evaluating liraglutide biosimilar RD12014 vs Victoza in a ratio (1:1) in 50 healthy male patients with T2D
- The results showed that the PK, safety and immunogenicity were similar b/w the liraglutide biosimilar RD12014 and the reference Victoza, TRAEs were reported in (22.4% vs 24.5%). The results were used to support an NDA in China
- The reference Victoza is currently used as an SC inj. for T2D & has been approved as an adjunct therapy to diet and exercise in the EU & the US along with approval in the US & China to prevent cardiovascular events in adults with T2D
Ref: CenterforBiosimilar | Image: Sunshine Lake Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
